Coronary Heart Disease
M-A: Comparison of bifurcation techniques for percutaneous coronary intervention.
21 Jun, 2022 | 10:50h | UTC
Prospective head-to-head comparative study: Functional stress imaging to predict abnormal coronary fractional flow reserve.
20 Jun, 2022 | 01:10h | UTC
Commentary on Twitter
Functional stress imaging to predict abnormal coronary fractional flow reserve: new insights from the PACIFIC 2 study!https://t.co/5N0dOW2Rem#PET #MRI #FFR #CCS #coronary #cardiotwitter @escardio @ESC_Journals pic.twitter.com/WCoA0cOgd9
— EHJ Editor-in-Chief (@ehj_ed) June 17, 2022
Under a https://creativecommons.org/licenses/by-nc/4.0/ license
Post Hoc Secondary Analysis of RCT: Rivaroxaban monotherapy is associated with better outcomes vs. combination therapy with antiplatelets in patients with atrial fibrillation and stable coronary artery disease.
17 Jun, 2022 | 11:07h | UTCRivaroxaban Monotherapy vs Combination Therapy With Antiplatelets on Total Thrombotic and Bleeding Events in Atrial Fibrillation With Stable Coronary Artery Disease: A Post Hoc Secondary Analysis of the AFIRE Trial – JAMA Cardiology (free for a limited period)
Commentaries:
Antithrombotic Therapy in Atrial Fibrillation and Coronary Artery Disease: Does Less Mean More? – JAMA Cardiology (free for a limited period)
Rivaroxaban Monotherapy Linked to Lower Event Risk in Patients with AF, Stable CAD – HCPLive
Commentary on Twitter
In this post-hoc study of the AFIRE RCT, recurrent event analyses showed that rivaroxaban monotherapy was associated with lower risks of total thrombotic and/or bleeding events than rivaroxaban plus antiplatelet therapy in patients with AF and stable CAD. https://t.co/TGwatvlrKR
— JAMA Cardiology (@JAMACardio) June 15, 2022